Health Hope Pharma ("HHP") is a clinical-stage oncology pharmaceutical company headquartered in Hong Kong, principally engaged in the development of novel oral anti-cancer drugs.
Numerous chemotherapeutic agents are P-glycoprotein (“P-gp”) substrates and are administered intravenously, since the P-gp efflux pump will actively pump the molecules back to the intestinal lumen
Encequidar inhibits the P-gp efflux pump to allow absorption of the molecules and render oral administration feasible
- A selective, potent P-glycoprotein (P-gp) inhibitor
- With minimal systemic bioavailability, acting mainly within the small intestine
- Enhances oral absorption of P-gp substrate, enabling oral drug delivery
- No significant systemic side effects to other organs and cells seen in clinical studies
- Encequidar is the international non-proprietary name (INN) for our novel P-gp pump inhibitor molecule
- Encequidar allows oral chemotherapy agents such as paclitaxel to achieve effective absorption
- Oral Paclitaxel + encequidar is paclitaxel combined with encequidar, enabling oral delivery of paclitaxel
- Expect lower incidence of toxicities associated with IV Paclitaxel C-Max and hypersensitivity-type reactions due to Cremophor solvent
